Key facts
- NeoChord’s last known valuation is $50.0M (Jun 2015).
- It has raised $95.4M across 13 recorded rounds; the latest was Seed Round ($493K) in Feb 2025.
- Notable investors include Deerfield Management, Mayo Clinic Ventures, Baird Capital, Andcor Companies, CHV Capital — 18 tracked in total.
- NeoChord has filed 21 Form Ds with the SEC since 2009, most recently Mar 2025 ($493K sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 13 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for NeoChord
Funding rounds
13 roundsAbout NeoChord
Developer of an artificial chordae delivery system designed to resolve and restore normal mitral valve function. The company's system is used for conducting a minimally invasive procedure when the native chordae tendinae have become elongated or ruptured, while the heart is beating and bypasses the need for conducting cardiopulmonary bypass or aortic cross-clamping, enabling surgeons to stop the leakage of blood backward through the mitral valve in patients suffering from mitral regurgitation.
- Sector
- Healthcare
- HQ
- Maple Grove, MN, United States
- Founded
- 2007
- Employees
- 18
- Website
- neochord.com/
- Ownership
- Privately Held (backing)
NeoChord doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeoChord shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeoChord in its N-PORT filings yet. We sweep new filings monthly.